Treace Medical Concepts (TMCI)
NASDAQ:TMCI
Want to see TMCI full AI Analyst Report?
TMCI Stock Chart & Stats
$1.94
-$0.15(-1.96%)
At close: 4:00 PM EST
$1.94
-$0.15(-1.96%)
Day’s Range― - ―
52-Week Range$1.17 - $7.78
Previous CloseN/A
Volume76.56K
Average Volume (3M)918.48K
Market Cap
$224.46M
Enterprise Value$228.47M
Total Cash (Recent Filing)$51.85M
Total Debt (Recent Filing)$13.55M
Price to Earnings (P/E)―
Beta2.59
Next Earnings
Aug 11, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.97
Shares Outstanding64,872,980
10 Day Avg. Volume1,009,218
30 Day Avg. Volume918,480
Financial Highlights & Ratios
PEG Ratio-0.79
Price to Book (P/B)1.77
Price to Sales (P/S)0.73
P/FCF Ratio-5.26
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue1.10
Enterprise Value/Gross Profit1.38
Enterprise Value/Ebitda-4.85
Forecast
1Y Price Target
$3.75Price Target Upside93.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.9
Revenue Forecast (FY)$206.33M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsTreace’s product economics deliver gross margins near 80%, a durable advantage for an implant-driven business. High product margins provide structural insulation for profitability as revenue scales, enabling reinvestment in training and sales even while operating leverage is still developing.
Product Portfolio Expansion & TAM GrowthMultiple new systems and upcoming commercial launches increase addressable markets materially. Expanding the platform beyond Lapiplasty diversifies procedure types and revenue streams, structurally raising long‑term growth potential and reducing dependence on a single product line.
Surgeon Adoption & Procedure MomentumA growing installed base (3,300 active surgeons) and rising adoption rates create recurring, procedure-linked demand for implants and disposables. Durable surgeon penetration and mid-single-digit procedure growth support predictable per-case revenue over time as training and clinical familiarity deepen.
Bears Say
Persistent Negative Cash FlowOperating and free cash flows have been persistently negative, meaning the company still funds operations via cash burn despite some narrowing. Continued negative cash flow constrains reinvestment, increases reliance on financing, and limits resilience to slower procedure demand.
Revenue Decline And Conservative GuidanceRecent top-line contraction and guidance that implies a full-year decline indicate the company is still working through mix and demand headwinds. Structural revenue weakness delays scale benefits, prolongs operating losses, and raises execution risk before back‑half recovery materializes.
ASP / Mix Headwinds From Lower‑priced MIS AdoptionWider adoption of lower‑ASP minimally invasive products reduces revenue per case even as procedure counts rise. This structural mix shift can depress near‑term revenue and cash conversion despite stable product gross margins, lengthening the path to profitability until pricing/mix normalizes.
Treace Medical Concepts News
TMCI FAQ
What was Treace Medical Concepts’s price range in the past 12 months?
Treace Medical Concepts lowest stock price was $1.17 and its highest was $7.78 in the past 12 months.
What is Treace Medical Concepts’s market cap?
Treace Medical Concepts’s market cap is $224.46M.
When is Treace Medical Concepts’s upcoming earnings report date?
Treace Medical Concepts’s upcoming earnings report date is Aug 11, 2026 which is in 70 days.
How were Treace Medical Concepts’s earnings last quarter?
Treace Medical Concepts released its earnings results on May 08, 2026. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.308 by $0.028.
Is Treace Medical Concepts overvalued?
According to Wall Street analysts Treace Medical Concepts’s price is currently Undervalued.
Does Treace Medical Concepts pay dividends?
Treace Medical Concepts does not currently pay dividends.
What is Treace Medical Concepts’s EPS estimate?
Treace Medical Concepts’s EPS estimate is -0.3.
How many shares outstanding does Treace Medical Concepts have?
Treace Medical Concepts has 64,872,980 shares outstanding.
What happened to Treace Medical Concepts’s price movement after its last earnings report?
Treace Medical Concepts reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.308. Following the earnings report the stock price went up 4.687%.
Which hedge fund is a major shareholder of Treace Medical Concepts?
Currently, no hedge funds are holding shares in TMCI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Treace Medical Concepts Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.75 (93.30% Upside)
$3.75 (93.30% Upside)
Hedge Fund Trend
Decreased
By 1.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $891.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.80%
12-Months-Change
Fundamentals
Return on Equity
-69.50%
Trailing 12-Months
Asset Growth
-10.56%
Trailing 12-Months
Company Description
Treace Medical Concepts
Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra Beach, Florida.
TMCI Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed picture: commercial execution and product momentum are clear positives (rapid adoption of new systems, expanding TAM, high gross margins, improved cash balance and reduced cash burn expectations), but near-term financials remain challenged (Q1 revenue down 10%, larger net and EBITDA losses, and ASP/mix headwinds). Management is taking a conservative posture—reaffirming guidance while highlighting the path to lapping mix headwinds in the back half of 2026 and expecting revenue growth to return in Q4. Overall, operational improvements and promising adoption trends offset but do not yet fully overcome the near-term revenue and profitability headwinds, leaving the situation balanced between encouraging commercial traction and ongoing financial pressure.View all TMCI earnings summariesTMCI Stock 12 Month Forecast
Average Price Target
$3.75
▲(93.30% Upside)
Technical Analysis
Ownership Overview
28.17% Insiders
8.22% Mutual Funds
20.48% Other Institutional Investors
35.89% Public Companies and
Individual Investors